Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and bodyweight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial

被引：0

作者：

Harrison, Stephen ^{[1
]}

Tomah, Shaheen ^{[2
]}

Suschak, John ^{[2
]}

Roberts, Scot ^{[2
]}

Yang, Jay ^{[2
]}

He, Liang ^{[2
]}

Georges, Bertrand ^{[2
]}

Rodwell-Green, Lakisha ^{[2
]}

Brown, Randy ^{[2
]}

Harris, M. Scott ^{[2
]}

Browne, Sarah ^{[2
]}

机构：

[1] Pinnacle Res, San Antonio, TX USA

[2] Altimmune Inc, Gaithersburg, MD USA

来源：

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

OS-063

引用

页码：S54 / S55

页数：2